Skip to main content
Clinical Trials/TCTR20180228005
TCTR20180228005
Not yet recruiting
Phase 1

The Comparison of anti-inflammatory versus supplement dose of selenium in mild Graves' orbitopathy

Ratchadapiseksompotch Research fund0 sites87 target enrollmentStarted: February 28, 2018Last updated:

Overview

Phase
Phase 1
Status
Not yet recruiting
Sponsor
Ratchadapiseksompotch Research fund
Enrollment
87

Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Years to 0 N/A (No limit) (—)
Sex
All

Inclusion Criteria

  • \-Mild thyroid eye disease group according to EUGOGO recommendation
  • \-Age above 18 years old
  • \-Normal thyroid hormone level (FT4, FT3\) for at least 6 months
  • \-Thyroid eye symptoms less than 24 months

Exclusion Criteria

  • \-Allergic reaction to selenium
  • \-History of selenium use
  • \-Pregnant or breast\-feeding
  • \-Recent history of orbital and eyelid surgery of less than 6 months

Investigators

Sponsor
Ratchadapiseksompotch Research fund

Similar Trials